RGEN,QTRX Stock Price and Quote

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: TECH MTD BIO BRKR A WAT HALO TMO DHR IDXX

| Held by: IJH VTI VB FBT VBK VXF MDY IBB SPMD IWR

Index	-
Market Cap	8.09B
Enterprise Value	7.99B
Income	51.40M
Sales	763.34M
Book/sh	37.33
Cash/sh	13.91
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	2000
IPO	Apr 29, 1986

P/E	157.87
Forward P/E	55.51
PEG	2.29
P/S	10.60
P/B	3.84
P/C	10.31
P/FCF	77.44
EV/EBITDA	44.91
EV/Sales	10.47
Quick Ratio	7.78
Current Ratio	9.20
Debt/Eq	0.33
LT Debt/Eq	0.32
Option/Short	Yes / Yes

EPS (ttm)	0.91
EPS next Y	2.58
EPS next Q	0.45
EPS this Y	17.19%
EPS next Y	28.92%
EPS next 5Y	24.21%
EPS past 3/5Y	-35.60% -4.91%
Sales past 3/5Y	-2.70% 15.05%
EPS Y/Y TTM	322.84%
Sales Y/Y TTM	17.36%
EPS Q/Q	42.58%
Sales Q/Q	14.83%
Earnings	May 05 BMO
EPS/Sales Surpr.	24.97% 1.15%

Insider Own	5.44%
Insider Trans	-0.15%
Inst Own	117.77%
Inst Trans	6.70%
ROA	1.78%
ROE	2.51%
ROIC	1.85%
Gross Margin	47.85%
Oper. Margin	7.79%
Profit Margin	6.73%
SMA20	4.81%
SMA50	14.24%
SMA200	2.79%
Trades

Shs Outstand	56.40M
Shs Float	53.34M
Short Float	10.74%
Short Ratio	4.97
Short Interest	5.73M
52W High	175.77 -18.41%
52W Low	100.99 42.00%
Volatility	3.92% 4.66%
ATR (14)	6.25
RSI (14)	60.95
Beta	1.04
Rel Volume	0.29
Avg Volume	1.15M
Volume	164,443

Perf Week	0.71%
Perf Month	10.20%
Perf Quarter	19.73%
Perf Half Y	-15.17%
Perf YTD	-12.48%
Perf Year	7.02%
Perf 3Y	-0.01%
Perf 5Y	-30.31%
Perf 10Y	416.78%
Recom	1.36
Target Price	175.17
Prev Close	143.94
Price	143.41
Change	-0.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-26	Upgrade	The Benchmark Company	Hold → Buy	$185
Jun-02-26	Resumed	Wolfe Research	Outperform	$145
May-15-26	Resumed	RBC Capital Mkts	Outperform	$160
Apr-17-26	Initiated	Rothschild & Co Redburn	Buy	$160
Oct-01-25	Initiated	HSBC Securities	Buy	$150
Sep-22-25	Upgrade	Evercore ISI	In-line → Outperform	$155
Jul-22-25	Resumed	Stephens	Overweight	$160
Jun-24-25	Initiated	Barclays	Overweight	$150
Apr-29-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$160
Mar-18-25	Initiated	Evercore ISI	In-line	$155
Feb-10-25	Initiated	TD Cowen	Buy	$200
Dec-17-24	Initiated	Canaccord Genuity	Hold	$165
Nov-14-24	Initiated	Wolfe Research	Peer Perform
Aug-28-24	Initiated	Wells Fargo	Overweight	$180
Jun-26-24	Upgrade	Deutsche Bank	Hold → Buy	$180 → $155
Jun-18-24	Initiated	Guggenheim	Neutral
Dec-04-23	Downgrade	The Benchmark Company	Buy → Hold
Jul-20-23	Initiated	Wells Fargo	Overweight	$185
Jul-05-23	Resumed	JP Morgan	Overweight	$220
Mar-28-23	Initiated	The Benchmark Company	Buy	$230

Show Previous Ratings

Jul-07-26 09:36AM	SpaceX initiated, Cloudflare upgraded: Wall Street's top analyst calls (The Fly)
May-22-26 07:30AM	Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference (GlobeNewswire)
May-20-26 07:30AM	Repligen Announces Publication of the Company's 2025 Corporate Sustainability Report (GlobeNewswire)
May-07-26 07:30AM	Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference (GlobeNewswire)
May-05-26 12:52PM	Repligen Corporation Q1 2026 Earnings Call Summary (Moby) +6.26%
07:36AM	Loading…
07:36AM	Repligen: Q1 Earnings Snapshot (Associated Press)
07:00AM	Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance (GlobeNewswire)
Apr-22-26 07:30AM	Repligen to Report First Quarter 2026 Financial Results (GlobeNewswire) -6.25%
Apr-17-26 09:36AM	Apple upgraded, Qualcomm downgraded: Wall Street's top analyst calls (The Fly)
07:30AM	Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network (GlobeNewswire)
Mar-05-26 07:30AM	Repligen Corporation to Present at Upcoming March Conferences (GlobeNewswire)
Mar-02-26 11:06PM	3 Reasons to Avoid RGEN and 1 Stock to Buy Instead (StockStory)
Feb-25-26 01:47PM	Analyst Report: Repligen Corporation (Morningstar Research)
09:10AM	Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
Feb-24-26 04:32PM	Repligen Corporation Q4 2025 Earnings Call Summary (Moby)
04:02PM	Loading…
04:02PM	Repligen Corp (RGEN) Q4 2025 Earnings Call Highlights: Strong Organic Growth and Strategic ... (GuruFocus.com)
12:49PM	Repligen Q4 Earnings Call Highlights (MarketBeat)
09:40AM	Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:47AM	Repligen: Q4 Earnings Snapshot (Associated Press Finance)
07:37AM	Repligen (NASDAQ:RGEN) Exceeds Q4 CY2025 Expectations (StockStory)
07:30AM	Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance (GlobeNewswire)
Feb-22-26 10:13PM	Repligen (RGEN) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-19-26 11:43PM	2 of Wall Street's Favorite Stocks Worth Investigating and 1 We Avoid (StockStory)
Feb-10-26 07:30AM	Repligen to Report Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-06-26 08:16AM	What Makes Repligen Corporation (RGEN) an Investment Choice? (Insider Monkey)
Feb-04-26 08:04PM	Analyst Report: Repligen Corporation (Morningstar Research)
Jan-26-26 11:01PM	3 Reasons to Sell RGEN and 1 Stock to Buy Instead (StockStory)
Jan-22-26 09:52PM	UBS Tags Repligen (RGEN) as Bioprocessing Leader for 2026, Cites 20% Order Growth and Reshoring Tailwinds (Insider Monkey)
Jan-14-26 02:15PM	Why Repligen (RGEN) Shares Are Sliding Today (StockStory)
Jan-06-26 07:30AM	Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair (GlobeNewswire)
07:30AM	Loading…
Dec-18-25 07:30AM	Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference (GlobeNewswire)
Dec-17-25 08:35AM	Here's Why Sands Capital Global Growth Fund Decided to Sell Repligen Corporation (RGEN) (Insider Monkey)
Dec-16-25 07:30AM	Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows (GlobeNewswire)
Dec-07-25 11:35PM	1 Volatile Stock to Target This Week and 2 We Turn Down (StockStory)
Dec-03-25 11:30AM	Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report? (Zacks)
Nov-26-25 07:30AM	Repligen Corporation to Present at Evercore Healthcare Conference (GlobeNewswire)
Nov-21-25 07:09PM	Analyst Report: Repligen Corporation (Morningstar Research) +5.28%
06:36PM	Why Repligen (RGEN) Stock Is Trading Up Today (StockStory)
Nov-06-25 10:31PM	Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN) (StockStory)
Nov-04-25 07:30AM	Repligen Corporation to Present at Upcoming November Conferences (GlobeNewswire)
12:32AM	5 Revealing Analyst Questions From Repligen's Q3 Earnings Call (StockStory)
Oct-30-25 07:45PM	Analyst Report: Repligen Corporation (Morningstar Research)
Oct-29-25 01:13PM	Analyst Report: Repligen Corporation (Morningstar Research)
11:18AM	RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down (Zacks)
09:40AM	RGEN Q3 Deep Dive: Robust Product Demand Offset by Margin Pressures and Guidance Reset (StockStory)
Oct-28-25 02:35PM	Why Repligen (RGEN) Shares Are Trading Lower Today (StockStory) -5.92%
08:45AM	Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
08:01AM	Repligen's (NASDAQ:RGEN) Q3 Sales Beat Estimates (StockStory)
07:40AM	Repligen: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance (GlobeNewswire)
Oct-27-25 09:22AM	Earnings To Watch: Repligen Corp (RGEN) Reports Q3 2025 Result (GuruFocus.com)
Oct-26-25 11:13PM	Repligen Earnings: What To Look For From RGEN (StockStory)
Oct-23-25 07:15PM	Analyst Report: Repligen Corporation (Morningstar Research)
10:00AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-21-25 11:40AM	ALKS vs. RGEN: Which Stock Is the Better Value Option? (Zacks)
10:00AM	Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to Decline (Zacks)
Oct-15-25 07:30AM	Repligen to Report Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-09-25 07:46AM	Is Repligen (RGEN) The Best Healthcare Stock to Buy Now? (Insider Monkey)
Oct-01-25 12:20PM	Why Is Repligen (RGEN) Stock Soaring Today (StockStory) +9.08%
Sep-30-25 04:05PM	Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know (StockStory) +7.72%
Sep-24-25 12:04AM	3 Reasons to Sell RGEN and 1 Stock to Buy Instead (StockStory)
Sep-22-25 11:31PM	Drug Development Inputs & Services Stocks Q2 Results: Benchmarking Repligen (NASDAQ:RGEN) (StockStory)
Sep-16-25 02:51PM	Repligen (RGEN) Stock Is Up, What You Need To Know (StockStory) +5.28%
Sep-12-25 02:26PM	Why Repligen (RGEN) Stock Is Down Today (StockStory)
Aug-22-25 03:40PM	Repligen, Revvity, Avantor, Fortrea, and Azenta Shares Skyrocket, What You Need To Know (StockStory)
07:30AM	Repligen Corporation to Present at Upcoming September Conferences (GlobeNewswire)
Aug-20-25 08:42AM	Do Options Traders Know Something About Repligen Stock We Don't? (Zacks)
Aug-12-25 12:53AM	RGEN Q2 Deep Dive: Chromatography and Filtration Drive Growth, Guidance Lifted Amid New Modalities Uncertainty (StockStory) +8.51%
12:35AM	5 Must-Read Analyst Questions From Repligen's Q2 Earnings Call (StockStory)
Aug-07-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jul-31-25 07:30AM	Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization (GlobeNewswire)
Jul-29-25 11:52PM	Analyst Report: Repligen Corporation (Morningstar Research)
02:26PM	Why Repligen (RGEN) Stock Is Up Today (StockStory)
08:45AM	Repligen (RGEN) Lags Q2 Earnings Estimates (Zacks)
08:09AM	Repligen's (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic (StockStory)
07:41AM	Repligen: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance (GlobeNewswire)
Jul-28-25 09:22AM	Repligen Corp (RGEN) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-27-25 11:06PM	Repligen (RGEN) Reports Q2: Everything You Need To Know Ahead Of Earnings (StockStory)
Jul-22-25 09:40AM	Netflix downgraded, Intel initiated: Wall Street's top analyst calls (The Fly)
Jul-21-25 09:45AM	Here's Why Repligen (RGEN) is a Strong Growth Stock (Zacks)
Jul-18-25 03:11PM	Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know (StockStory) -6.28%
12:03AM	3 Reasons RGEN is Risky and 1 Stock to Buy Instead (StockStory)
Jul-17-25 07:30AM	Repligen to Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-24-25 02:18PM	5 Insightful Analyst Questions From Repligen's Q1 Earnings Call (StockStory)
Jun-16-25 08:00AM	908 Devices Appoints Christopher D. Brown to its Board of Directors (Business Wire)
Jun-04-25 11:36PM	Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
Jun-03-25 11:32PM	Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers (StockStory)
Jun-02-25 01:36PM	Do Options Traders Know Something About Repligen (RGEN) Stock We Don't? (Zacks)
May-29-25 11:30AM	Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report? (Zacks)
May-27-25 07:30AM	Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report (GlobeNewswire)
May-22-25 07:30AM	Repligen Corporation to Present at William Blair Growth Conference (GlobeNewswire)
May-09-25 12:36AM	1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar (StockStory)
May-07-25 07:30AM	Repligen Corporation to Present at Upcoming May Investor Conferences (GlobeNewswire)
May-02-25 11:40AM	QGEN or RGEN: Which Is the Better Value Stock Right Now? (Zacks)
08:18AM	Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare (Insider Monkey)
May-01-25 12:11PM	Jim Cramer on Repligen Corporation (RGEN): 'I'm Not Quite Ready to Stick My Neck Out on This One' (Insider Monkey)
Apr-30-25 04:19PM	RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty (StockStory)
10:55AM	Analyst Report: Repligen Corporation (Morningstar Research)
09:07AM	Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

PresidentMr. Olivier Loeillot

CFO & Chief Compliance OfficerMr. Jason K. Garland

Chief Operating OfficerMr. James R. Bylund

AdvisorMr. Anthony J. Hunt

Senior Vice President of Research & DevelopmentMr. Ralf Kuriyel

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Garland Jason K	CFO	Jun 25 '26	Sale	145.00	733	106,285	19,359	Jun 26 04:05 PM
Garland Jason K	Officer	Jun 25 '26	Proposed Sale	145.00	733	106,285		Jun 25 01:55 PM
MUIR GLENN P	Director	May 07 '26	Option Exercise	38.76	2,434	94,342	39,056	May 08 02:48 PM
Loeillot Olivier	Chief Executive Officer	Apr 21 '26	Sale	140.00	3,832	536,480	54,246	Apr 22 01:26 PM
Loeillot Olivier	Officer	Apr 21 '26	Proposed Sale	140.00	3,832	536,480		Apr 21 12:44 PM
DAWES KAREN A	Director	Dec 17 '25	Sale	161.00	275	44,275	91,821	Dec 18 04:30 PM
MUIR GLENN P	Director	Dec 16 '25	Option Exercise	26.12	3,366	87,920	36,622	Dec 17 04:30 PM
DAWES KAREN A	Director	Dec 17 '25	Proposed Sale	161.00	275	44,275		Dec 17 04:28 PM
Loeillot Olivier	Chief Executive Officer	Nov 25 '25	Sale	170.00	7,041	1,196,970	35,898	Nov 26 04:30 PM
Loeillot Olivier	Officer	Nov 25 '25	Proposed Sale	170.00	7,041	1,196,970		Nov 25 12:06 PM
Bylund James	Chief Operating Officer	Nov 18 '25	Sale	151.21	2,191	331,301	21,520	Nov 19 04:30 PM
Bylund James	Officer	Nov 18 '25	Proposed Sale	151.21	2,191	331,304		Nov 18 04:10 PM
Hunt Anthony	Director	Nov 13 '25	Option Exercise	33.87	2,952	99,984	83,695	Nov 14 04:30 PM
Hunt Anthony	Director	Nov 13 '25	Sale	154.61	20,000	3,092,278	80,743	Nov 14 04:30 PM
Hunt Anthony	Director	Nov 12 '25	Option Exercise	33.87	25,000	846,750	125,743	Nov 13 04:30 PM
Hunt Anthony	Director	Nov 12 '25	Sale	156.88	25,000	3,921,940	100,743	Nov 13 04:30 PM
Hunt Anthony	Director	Nov 13 '25	Proposed Sale	154.62	20,000	3,092,327		Nov 13 04:11 PM
Hunt Anthony	Director	Nov 12 '25	Proposed Sale	156.88	25,000	3,921,981		Nov 12 04:37 PM
Hunt Anthony	Director	Sep 10 '25	Option Exercise	33.87	20,000	677,400	129,854	Sep 11 02:55 PM
Hunt Anthony	Director	Sep 10 '25	Sale	120.52	29,111	3,508,389	100,743	Sep 11 02:55 PM
Hunt Anthony	Director	Sep 10 '25	Proposed Sale	120.52	29,111	3,508,378		Sep 10 04:22 PM
Madaus Martin D	Director	Aug 08 '25	Buy	112.13	1,800	201,830	1,800	Aug 12 12:47 PM

Peers: RXST TLSI INGN LUCD MASS SENS SGHT BFLY BDSX IMDX

| Held by: IWM VTI IWN VXF IBB SCHA FESM VTWO DFMC IWC

Index	RUT
Market Cap	181.56M
Enterprise Value	117.63M
Income	-104.19M
Sales	144.98M
Book/sh	6.00
Cash/sh	2.11
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	450
IPO	Dec 07, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	1.25
P/B	0.64
P/C	1.83
P/FCF	-
EV/EBITDA	-
EV/Sales	0.81
Quick Ratio	2.70
Current Ratio	3.72
Debt/Eq	0.13
LT Debt/Eq	0.10
Option/Short	Yes / Yes

EPS (ttm)	-2.37
EPS next Y	-1.33
EPS next Q	-0.40
EPS this Y	48.84%
EPS next Y	-3.25%
EPS next 5Y	22.35%
EPS past 3/5Y	2.27% -18.72%
Sales past 3/5Y	9.59% 9.97%
EPS Y/Y TTM	-90.71%
Sales Y/Y TTM	6.85%
EPS Q/Q	29.49%
Sales Q/Q	20.05%
Earnings	May 06 AMC
EPS/Sales Surpr.	27.92% -1.16%

Insider Own	12.25%
Insider Trans	0.06%
Inst Own	75.37%
Inst Trans	3.82%
ROA	-27.30%
ROE	-34.81%
ROIC	-33.66%
Gross Margin	44.22%
Oper. Margin	-72.41%
Profit Margin	-71.86%
SMA20	3.26%
SMA50	16.72%
SMA200	-24.07%
Trades

Shs Outstand	47.06M
Shs Float	41.33M
Short Float	10.83%
Short Ratio	3.65
Short Interest	4.48M
52W High	8.77 -56.05%
52W Low	2.39 60.94%
Volatility	7.39% 9.91%
ATR (14)	0.33
RSI (14)	53.31
Beta	1.05
Rel Volume	0.23
Avg Volume	1.23M
Volume	141,739

Perf Week	-10.98%
Perf Month	24.74%
Perf Quarter	16.80%
Perf Half Y	-41.86%
Perf YTD	-39.40%
Perf Year	-34.17%
Perf 3Y	-84.29%
Perf 5Y	-93.53%
Perf 10Y	-
Recom	3.00
Target Price	4.33
Prev Close	3.98
Price	3.85
Change	-3.16%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-11-25	Downgrade	Canaccord Genuity	Buy → Hold	$5
Feb-01-24	Initiated	Scotiabank	Sector Outperform	$30
Sep-25-23	Upgrade	Canaccord Genuity	Hold → Buy	$25 → $32
Aug-08-23	Upgrade	SVB Securities	Market Perform → Outperform	$30
May-23-23	Upgrade	Goldman	Neutral → Buy	$13 → $27
Aug-15-22	Downgrade	Canaccord Genuity	Buy → Hold	$40 → $12
Aug-09-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$35 → $15
Aug-09-22	Downgrade	Cowen	Outperform → Market Perform	$38 → $18
Mar-02-22	Upgrade	Goldman	Sell → Neutral	$40
Oct-15-21	Resumed	Cowen	Outperform
Jun-04-21	Initiated	Goldman	Sell	$53

Show Previous Ratings

Jun-23-26 09:55PM	TRIB, QTRX, RCON: Why These Stocks Are Surging After-Hours Today (Stocktwits) -7.74% +17.39%
Jun-16-26 04:01PM	Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.88%
Jun-09-26 08:03AM	Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer (Business Wire)
Jun-04-26 08:02AM	Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics (Business Wire) +7.65%
Jun-03-26 08:01AM	Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
04:01PM	Loading…
May-26-26 04:01PM	Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-12-26 04:01PM	Quanterix Announces Planned Transition of Chief Financial Officer (Business Wire)
May-06-26 04:01PM	Quanterix Releases Financial Results for the First Quarter of 2026 (Business Wire) -16.41%
Apr-24-26 08:33AM	Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026 (Business Wire)
Apr-17-26 08:33AM	AidaBREAST Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology (Business Wire)
Apr-15-26 08:33AM	Quanterix Debuts Content Innovation Engine at AACR 2026 (Business Wire) +6.19%
Mar-27-26 04:00PM	Quanterix Corporation Announces Date of 2026 Annual Meeting (Business Wire) -8.21%
Mar-03-26 08:30AM	Quanterix Corporation Q4 2025 Earnings Call Summary (Moby) -7.27%
12:01AM	Quanterix Corp (QTRX) Q4 2025 Earnings Call Highlights: Revenue Surge Amidst Strategic Shifts (GuruFocus.com)
Mar-02-26 05:32PM	Quanterix Q4 Earnings Call Highlights (MarketBeat)
05:10PM	Loading…
05:10PM	Quanterix Corporation (QTRX) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:01PM	Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025 (Business Wire)
08:33AM	Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide (Business Wire)
Feb-27-26 07:21AM	Quanterix Corp (QTRX) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-26-26 06:00PM	Curaleaf Holdings, Inc. (CURLF) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +6.84%
08:33AM	Quanterix to Participate in Upcoming Investor Conferences (Business Wire)
Feb-20-26 08:33AM	Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 (Business Wire)
Feb-04-26 12:57PM	Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test (Zacks)
Feb-03-26 08:33AM	Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimers Disease Detection (Business Wire)
Jan-21-26 08:33AM	Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling (Business Wire)
Jan-16-26 04:01PM	Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.92% -5.14%
Jan-08-26 04:30PM	Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 (Business Wire) +23.81%
Dec-22-25 07:30AM	Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence (Business Wire)
Nov-20-25 04:15PM	Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth (Business Wire) +12.69%
Nov-17-25 05:30PM	Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring (Business Wire)
12:02AM	Loading…
Nov-11-25 12:02AM	Quanterix Corp (QTRX) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com)
Nov-10-25 05:10PM	Quanterix Corporation (QTRX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Quanterix Releases Financial Results for the Third Quarter of 2025 (Business Wire)
Nov-07-25 07:35AM	Sanuwave Health Inc. (SNWV) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:22AM	Earnings To Watch: Quanterix Corp (QTRX) Reports Q3 2025 Result (GuruFocus.com)
Nov-03-25 07:00AM	Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025 (Business Wire)
Oct-02-25 12:00PM	All You Need to Know About Quanterix (QTRX) Rating Upgrade to Buy (Zacks)
Aug-21-25 04:30PM	Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit (Business Wire)
Aug-12-25 09:35AM	Down 24.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Quanterix (QTRX) (Zacks)
Aug-11-25 07:00AM	Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
Aug-07-25 06:35PM	Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -13.79%
04:06PM	Quanterix Releases Financial Results for the Second Quarter of 2025 (Business Wire)
Aug-04-25 04:02PM	Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
09:30AM	Quanterix Announces Cooperation Agreement with Kent Lake Capital (Business Wire)
Jul-28-25 07:00AM	Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC (Business Wire) +10.94%
Jul-24-25 08:45AM	Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Jul-11-25 05:00PM	Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-08-25 09:07AM	Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum (Business Wire)
Jun-23-25 07:30AM	Quanterix Expands Reach with IVD and Large Reference Labs (Business Wire)
Jun-11-25 08:00AM	Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders (PR Newswire)
Jun-06-25 09:41AM	Quanterix to Present at Goldman Sachs Global Healthcare Conference (Business Wire)
May-23-25 02:21PM	Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal (PR Newswire)
09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
May-13-25 03:09AM	Quanterix Corp (QTRX) Q1 2025 Earnings Call Highlights: Record Consumables Revenue Amidst ... (GuruFocus.com) -19.02%
May-12-25 05:10PM	Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.52%
04:01PM	Quanterix Releases Financial Results for the First Quarter of 2025 (Business Wire)
May-09-25 09:42AM	Earnings To Watch: Quanterix Corp (QTRX) Reports Q1 2025 Result (GuruFocus.com)
May-07-25 07:40PM	Phibro Animal Health (PAHC) Q3 Earnings Beat Estimates (Zacks)
May-05-25 07:00AM	Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025 (Business Wire)
Apr-30-25 08:00AM	Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders (Business Wire)
Apr-29-25 07:00AM	Quanterix and Akoya Biosciences Announce Amended Merger Agreement (Business Wire)
Apr-17-25 08:30AM	Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders (Business Wire)
Apr-14-25 08:00AM	Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences (Business Wire) +7.69%
Apr-07-25 08:15AM	Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya (Business Wire) -12.96%
Apr-02-25 09:41AM	Quanterix: Still Many, Many Questions (Seeking Alpha)
Apr-01-25 01:00AM	Quanterix Showcases Innovation Powered by Simoa at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit (Business Wire)
Mar-24-25 11:03AM	Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences (Business Wire)
Mar-19-25 04:10PM	SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN (PR Newswire)
Mar-18-25 09:18AM	Q4 2024 Quanterix Corp Earnings Call (Thomson Reuters StreetEvents)
03:01AM	Quanterix Corp (QTRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com)
Mar-17-25 04:01PM	Quanterix Releases Financial Results for the Fourth Quarter of 2024 (Business Wire)
04:00PM	Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Todays Earnings Call (Business Wire)
04:00PM	Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results (GlobeNewswire)
Mar-13-25 01:00PM	Quanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025 (Business Wire)
Mar-11-25 08:00AM	Kent Lake Issues Investor Presentation Detailing Opposition to Quanterixs Proposed Merger with Akoya Biosciences (Business Wire)
Mar-03-25 08:00AM	Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board (Business Wire) -6.59%
06:00AM	Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition (Business Wire)
Feb-18-25 03:40PM	Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Companys Proposed Merger with Akoya Biosciences (Business Wire)
Jan-14-25 07:00AM	Quanterix Provides Update on Financial Performance (Business Wire) -5.93%
Jan-10-25 07:00AM	Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers (Business Wire) -19.69%
Jan-06-25 09:30AM	David R. Walt Receives National Medal of Technology and Innovation (Business Wire)
Jan-02-25 04:26PM	Quanterix to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) +12.27%
Dec-27-24 04:33AM	Down More Than 60%: Analysts Expect These 2 Beaten-Down Stocks to Rebound in 2025 (TipRanks)
Dec-17-24 06:59AM	Quanterix Expands Capabilities with Strategic Acquisition of EMISSION (Business Wire)
Nov-22-24 05:00PM	Quanterix Announces Receipt of Expected Notice from Nasdaq (Business Wire) +5.70%
07:54AM	Wolf Haldenstein Adler Freeman and Herz LLP announces that it is investigating Quanterix Corporation for potential violations of securities laws (GlobeNewswire)
Nov-21-24 07:00AM	Wolf Haldenstein Adler Freeman and Herz LLP announces that it is investigating Quanterix Corporation for potential violations of securities laws (PR Newswire) +6.35%
Nov-13-24 02:18AM	Quanterix Corp (QTRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Instrument ... (GuruFocus.com) -18.26%
Nov-12-24 04:01PM	Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024 (Business Wire)
Nov-11-24 07:14AM	Quanterix Corp (QTRX) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-05-24 04:00PM	Quanterix To Report Third Quarter 2024 Financial Results on November 12, 2024 (Business Wire) +5.99%
Oct-28-24 04:30PM	New Multi-Marker Blood Test from Lucent Diagnostics Increases the Number of Patients Receiving Early Alzheimer's Disease Diagnostic Information (Business Wire) +5.02%
Oct-09-24 05:55PM	Quanterix Corp (QTRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amid Regional ... (GuruFocus.com)
Oct-02-24 04:00PM	Quanterix Welcomes Ivana Magovevi-Liebisch, Ph.D., J.D. to Board of Directors (Business Wire)
Sep-30-24 04:00PM	Quanterix Announces Commercialization of p-Tau 217 Test Kit (Business Wire)
Aug-29-24 04:00PM	Quanterix to Participate at the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-19-24 04:32PM	Jeffrey Elliott Appointed to Quanterixs Board of Directors (Business Wire) +7.66%
Aug-15-24 07:18PM	Insider Buying: President & CEO Masoud Toloue Acquires Shares of Quanterix Corp (QTRX) (GuruFocus.com) +9.25%
Aug-08-24 05:10PM	Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -14.82%
04:00PM	Quanterix Releases Financial Results for the Second Quarter of 2024 (Business Wire)

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Executive ChairMr. William P. Donnelly

Co-Founder & Chairman of Scientific Advisory BoardDr. David R. Walt Ph.D.

PresidentMr. Everett V. Cunningham

CFO & TreasurerMr. Jason Faessler

Chief Operating OfficerMr. Anthony Catalano

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Meadows Benjamin	Chief Commercial Officer	May 12 '26	Buy	2.77	3,500	9,695	3,500	Jun 12 05:32 PM
Sriram Vandana	Chief Financial Officer	Sep 12 '25	Buy	4.79	4,150	19,878	87,200	Sep 17 10:24 AM

RGEN

Repligen Corp

QTRX

Quanterix Corp

Upgrade your Finviz experience